Predicting progression to lymphoma in Sjögren's syndrome patients

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 501-512

  Giannouli, Stavroula ^a   Voulgarelis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

BAFF; cryoglobulinemia; hypocomplementemia; lymphopenia; marginal zone B cell lymphoma; swelling of the parotid gland

Indexed keywords

ADVERSE OUTCOME; APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; GENETIC POLYMORPHISM; GENOMIC INSTABILITY; GERMINAL CENTER; HEMATOLOGIC DISEASE; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; INCIDENCE; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; MICROSCOPY; MONOCLONAL IMMUNOGLOBULINEMIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PURPURA; REVIEW; RISK FACTOR; SALIVARY GLAND; SJOEGREN SYNDROME; SOMATIC HYPERMUTATION; T LYMPHOCYTE; TISSUE INJURY;

DISEASE PROGRESSION; HUMANS; LYMPHOMA; PROGNOSIS; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 84896927637     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.872986     Document Type: Review

References (83)

1. Martens PB, Pillemer SR, Jacobsson LT, et al. Survivorship in a population based cohort of patients with Sjogren's syndrome, 1976-1992. J Rheumatol 1999;26:1296-300
2. Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72
3. Kruize AA, Hené RJ, van der Heide A, et al. Long-term follow-up of patients with Sjogren's syndrome. Arthritis Rheum 1996;39:297-303
4. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9
5. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjogren's syndrome in north-west Greece. 1982-2003. Rheumatology (Oxford) 2006;45:187-91
6. Brito-Zero'n P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-62
7. Ramos-Casals M, Brito-Zero'n P, Yague J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2005;44:89-94
8. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000;29:296-304
9. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7
10. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Inter Med 1978;89:888-92
11. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999;42:1765-72
12. Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjogren's syndrome. Clin Exp Immunol 1972;10:199-221
13. Anaya JM, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 1996;25:337-46
14. Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997;24: 2376-80
15. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren's syndrome A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65: 796-803
16. Solans-Laqué R, Lo'pez-Hernandez A, Bosch-Gil JA, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 2011;41: 415-23
17. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165: 2337-44
18. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60
19. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8: 201-2044
20. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
21. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87.
22. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites and are not associated with viruses. Blood 1997;90:766-75
23. Mariette X. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 1999;33(1-2)):93-9
24. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009;88:284-93
25. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125: 398-405
26. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38
27. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjogren syndrome or hepatitis C virus infection. Br J Haematol 2004;126:43-9
28. Inagaki H, Chan JK, Ng JW, et al. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features. Am J Pathol 2002;160:1435-43
29. Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol 2011;38:2198-208
30. Tzioufas AG, Manoussakis MN, Costello R, et al. Cryoglobulinemia in autoimmune rheumatic diseases: evidence of circulating monoclonal cryoglobulins in patients with primary Sjogren's syndrome. Arthritis Rheum 1986;29:1098-104
31. Moutsopoulos HM, Tzioufas AG, Bai MK, et al. Association of serum IgM kappa monoclonicity in patients with Sjogren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands. Ann Rheum Dis 1990;49:929-31
32. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996;39:767-72
33. De Vita S, Quartuccio L, Salvin S, et al. Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. Rheumatology (Oxford) 2012;51:627-33
34. Bassig BA, Zheng T, Zhang Y, et al. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen 2012;53:145-51
35. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8(5):e59868
36. Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010;49:571-7
37. Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 1998;28:80-7
38. Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011;70:1363-8
39. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000;43: 94-102
40. De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjogren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001;27:757-66
41. Abbondanzo SL. Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 2001;5:246-54
42. De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjogren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis 2001;27:757-66
43. Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:335-41
44. Marx RE, Hartman KS, Rethman KV. A prospective study comparing incisional labial to incisional parotid biopsies in the detection and confirmation of sarcoidosis, Sjogren's disease, sialosis and lymphoma. J Rheumatol 1988;15:621-9
45. Brito-Zero'n P, Soria N, Munoz S, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjogren's syndrome. Semin Arthritis Rheum 2009;38:389-95
46. Cesana C, Barbarano L, Miqueleiz S, et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 2005;5:261-4
47. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-15
48. Kirtava Z, Blomberg J, Bredberg A, et al. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjogren's syndrome. Clin Exp Rheumatol 1995;13:609-16
49. Henriksson G, Manthorpe R, Bredberg A, Antibodies to CD4 in primary Sjogren's syndrome. Rheumatology (Oxford) 2000;39:142-7
50. Mandl T, Bredberg A, Jacobsson LT, et al. CD4+ T-lymphocytopenia-a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren's syndrome. J Rheumatol 2004;31:726-8
51. Ramos-Casals M, Trejo O, Garc?́a-Carrasco M, et al. Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9
52. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002;46: 2160-71
53. Spachidou MP, Bourazopoulou E, Maratheftis CI, et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome. Clin Exp Immunol 2007;147:497-503
54. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum 2004;50: 2897-902
55. Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998;91: 1864-72
56. Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H)genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000;95:3878-84
57. Martin T, Weber JC, Levallois H, et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000;43:908-16
58. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005;201:1229-41
59. Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997;89:3335-44
60. Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 2007;34:2044-9
61. Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003;48:3187-201
62. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren's syndrome. Arthritis Rheum 2010;62:2605-10
63. Le Pottier L, Devauchelle V, Fautrel A, et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 2009;182:3540-7
64. Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 2007;179:4929-38
65. Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2007;19: 406-13
66. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007;9:218
67. Groom J, Kalled SL, Cutler AH, et al. Association of. BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109: 59-68
68. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
69. Daridon C, Pers JO, Devauchelle V, et al. Identification of transitional type II. B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006;54:2280-8
70. Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8:R51
71. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71
72. Jonsson MV, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005;25:189-201
73. Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88
74. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF. APRIL and human B cell disorders. Semin Immunol 2006;18:305-17
75. Bossen C, Schneider P. BAFF. APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75
76. He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79
77. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52: 276-81
78. Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun 2013. [Epub ahead of print]
79. Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013;65:1085-96
80. Lisovsky M, Braun SE, Ge Y, et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996;10: 1012-18
81. Antonysamy MA, Thomson AW. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 2000;12: 87-100
82. Tobo'n GJ, Renaudineau Y, Hillion S, et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2010;62: 3447-56
83. Tobo'n GJ, Saraux A, Gottenberg JE, et al. The FMS-like tyrosine kinase 3-ligand may be biological marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2013;65:3218-27